MRK240712C150000
- 0.02
- 0.000.00%
Merck & Co Newsroom
Morgan Stanley Sees $180B Patent Cliff, $380B Deal Capacity Fueling Biopharma M&A
Healthcare Sector at an 'Inflection Point': Strategist
Top Research Reports for Exxon Mobil, Merck & Qualcomm
Unusual Options Activity: RDDT, GXO and Others Attract Market Bets, RDDT V/OI Ratio Reaches 200.2
EST Jul 12th Closing Delivery - In the last three hours of trading, 10 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options
Merck's Acquisition of EyeBio Finalized
Merck (NYSE:MRK) is trending on Friday. The company announced the acquisition of EyeBio, introducing a novel candidate to Merk's pipeline, Restoret.What To Know: Restoret has shown promising results
Novo's Ozempic Linked to Improved Brain Health: Study
Sector Update: Health Care Stocks Mixed Premarket Friday
Health care stocks were mixed premarket Friday with the Health Care Select Sector SPDR Fund (XLV) down 0.2% and the iShares Biotechnology ETF (IBB) up almost 1% recently.Immutep (IMMP) rose past 17%
Investors in Merck (NYSE:MRK) Have Seen Notable Returns of 81% Over the Past Three Years
Sector Update: Health Care
Health care stocks were mixed premarket Friday with the Health Care Select Sector SPDR Fund (XLV) down 0.8% and the iShares Biotechnology ETF (IBB) 0.6% higher recently.Immutep (IMMP) shares rose
Australia Based Cancer Focused Immutep's Lead Cancer Drug Shows 'Meaningful Response' In Untreated Head & Neck Cancer, Stock Soars
Friday, Immutep Limited (NASDAQ:IMMP) released results from Cohort B of the TACTI-003 (KEYNOTE-PNC-34) Phase 2b trial of eftilagimod alfa (efti) in combination with Merck & Co Inc (NYSE:MRK) Keytruda (pembrolizumab) as first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma patients with negative PD-L1 expression.
Express News | Merck & Co Inc - Will Record Charge of About $1.3 Bln, or About $0.50 per Share in Q3 of 2024, Which Will Be Included in Non-Gaap Results
Express News | Merck Completes Acquisition of Eyebio
Immutep Achieves 'Positive' Results From Cohort B of Phase 2B Cancer Trial
Immutep (IMMP) said late Thursday it achieved "positive" results from cohort B of the TACTI-003 phase 2b trial evaluating the company's eftilagimod alfa in combination with Merck's (MRK) Keytruda as a potential first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma in patients with negative PD-L1 expression.
Beyond The Numbers: 6 Analysts Discuss Merck & Co Stock
During the last three months, 6 analysts shared their evaluations of Merck & Co (NYSE:MRK), revealing diverse outlooks from bullish to bearish.The table below summarizes their recent ratings,
Merck Is Maintained at Equal-Weight by Morgan Stanley
Merck Is Maintained at Equal-Weight by Morgan
Merck & Co Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/11/2024 4.86% Morgan Stanley $132 → $134 Maintains Equal-Weight 06/20/2024 21.29% Cantor Fitzgerald $15
United Therapeutics Cut at Morgan Stanley on Risk-reward Setup
Express News | Merck & Co Inc : Morgan Stanley Raises Target Price to $134 From $132
Morgan Stanley Adjusts Price Target on Merck to $134 From $132
Merck & Company (MRK) has an average rating of outperform and price targets ranging from $120 to $155, according to analysts by Capital IQ.
Morgan Stanley Maintains Merck & Co(MRK.US) With Hold Rating, Raises Target Price to $134
Morgan Stanley analyst Terence Flynn maintains $Merck & Co(MRK.US)$ with a hold rating, and adjusts the target price from $132 to $134.According to TipRanks data, the analyst has a success rate of 64.